Skip to content
Parakho

Mankind Pharma Ltd

NSE MANKINDBSE 543904mankindpharma.com

Q1 FY27, unaudited

Revenue
₹4,030.59 Cr
Profit after tax
₹574.09 Cr

As filed with the exchange, consolidated basis.

Board meeting

Mankind Pharma Ltd has given BSE notice of a board meeting on 26 Oct 2026 to consider Q2 FY27 results. Notice · Results calendar

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations4,030.59+12.89%14,277.64
Other income45.00−43.67%358.79
Total income4,075.59+11.65%14,636.43
Employee benefit expense913.50+16.61%3,183.90
Finance costs109.98−35.55%639.28
Depreciation & amortisation225.70+3.21%886.18
Total expenses3,310.08+6.33%12,185.69
Profit before tax765.51+42.47%2,320.99
Tax expense195.36+103.78%394.58
Profit after tax574.09+29.12%1,938.10
Total comprehensive income553.78+24.76%1,995.14
Earnings per share
Earnings per share, basic₹13.76₹46.35
Earnings per share, diluted₹13.74₹46.28

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

Q1 FY27

Mankind Pharma reported Q1 FY27 revenue of Rs 4,031 crore, up 13% year-on-year, with EBITDA margin expanding 250 basis points to 26.3%. Domestic business excluding Consumer Healthcare grew 11% year-on-year, led by chronic and BSV specialty portfolios, while international business grew 29% and Consumer Healthcare revenue was Rs 246 crore, partly impacted by a discontinued cash and carry business. Management discussed gross margin drivers, working capital trends, GLP-1 launch strategy, and provided updates on BSV, acute and chronic therapy performance across the quarter.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.

Read the full summary

Earlier calls: Q4 FY26 · All quarters

Filings

12 shown · 76 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 12 Oct 2026.